Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Immunol. 2022 Aug 10;13:929221. doi: 10.3389/fimmu.2022.929221. eCollection 2022.
The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some patients are resistant to this treatment, leaving them with limited options. Therefore, strategies to overcome resistance to CAR-T cell therapy are needed. We retrospectively studied three R/R diffuse large B-cell lymphoma patients who were resistant to CAR-T cell therapy and whose disease was controlled after receiving pembrolizumab, 21D4 CAR-T cells, or ibrutinib and venetoclax. Some promising prevention and treatment strategies to overcome treatment resistance are also discussed.
嵌合抗原受体 (CAR) T 细胞疗法的出现改变了恶性肿瘤治疗的模式，特别是 CD19 靶向 CAR-T 细胞疗法在治疗复发/难治性 (R/R) B 细胞恶性肿瘤中的应用。尽管 CAR-T 细胞疗法具有广阔的应用前景，但部分患者对该治疗方法存在抵抗，使得他们的治疗选择有限。因此，需要寻找克服 CAR-T 细胞治疗抵抗的策略。本研究回顾性分析了 3 例接受 CAR-T 细胞治疗后耐药的 R/R 弥漫性大 B 细胞淋巴瘤患者，他们在接受帕博利珠单抗、21D4 CAR-T 细胞、伊布替尼和维奈托克治疗后疾病得到控制。同时，还讨论了一些有前途的预防和治疗策略，以克服治疗抵抗。
Zotero 插件
